Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
RXII's Cash-to-Debt is ranked higher than
75% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. RXII: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
RXII' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.35  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.76
RXII's Equity-to-Asset is ranked higher than
64% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. RXII: 0.76 )
Ranked among companies with meaningful Equity-to-Asset only.
RXII' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.04  Med: 0.41 Max: 0.85
Current: 0.76
-1.04
0.85
Interest Coverage No Debt
RXII's Interest Coverage is ranked higher than
70% of the 463 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. RXII: No Debt )
Ranked among companies with meaningful Interest Coverage only.
RXII' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Piotroski F-Score: 3
Altman Z-Score: -20.47
Beneish M-Score: -3.91
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -48936.84
RXII's Operating Margin % is ranked lower than
98% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -92.73 vs. RXII: -48936.84 )
Ranked among companies with meaningful Operating Margin % only.
RXII' s Operating Margin % Range Over the Past 10 Years
Min: -48936.84  Med: -12903.64 Max: -5250.38
Current: -48936.84
-48936.84
-5250.38
Net Margin % -48794.74
RXII's Net Margin % is ranked lower than
98% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -81.52 vs. RXII: -48794.74 )
Ranked among companies with meaningful Net Margin % only.
RXII' s Net Margin % Range Over the Past 10 Years
Min: -48794.74  Med: -12836.36 Max: -5244.36
Current: -48794.74
-48794.74
-5244.36
ROE % -132.90
RXII's ROE % is ranked lower than
85% of the 756 Companies
in the Global Biotechnology industry.

( Industry Median: -38.58 vs. RXII: -132.90 )
Ranked among companies with meaningful ROE % only.
RXII' s ROE % Range Over the Past 10 Years
Min: -336.41  Med: -257.87 Max: -132.9
Current: -132.9
-336.41
-132.9
ROA % -106.68
RXII's ROA % is ranked lower than
85% of the 855 Companies
in the Global Biotechnology industry.

( Industry Median: -33.01 vs. RXII: -106.68 )
Ranked among companies with meaningful ROA % only.
RXII' s ROA % Range Over the Past 10 Years
Min: -603.25  Med: -203.85 Max: -72.95
Current: -106.68
-603.25
-72.95
ROC (Joel Greenblatt) % -6342.43
RXII's ROC (Joel Greenblatt) % is ranked lower than
82% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -496.85 vs. RXII: -6342.43 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
RXII' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -11172.8  Med: -4903.33 Max: -3597.18
Current: -6342.43
-11172.8
-3597.18
GuruFocus has detected 1 Warning Sign with RXi Pharmaceuticals Corp $RXII.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» RXII's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

RXII Guru Trades in Q1 2016

Jim Simons 950,900 sh (-87.79%)
» More
Q2 2016

RXII Guru Trades in Q2 2016

Jim Simons 142,580 sh (+49.94%)
» More
Q3 2016

RXII Guru Trades in Q3 2016

Jim Simons 181,780 sh (+27.49%)
» More
Q4 2016

RXII Guru Trades in Q4 2016

Jim Simons 229,980 sh (+26.52%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:RXII

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:VRTHF, OTCPK:WLDFF, OTCPK:REPCF, OTCPK:LIXT, OTCPK:PPCH, NAS:WINT, OTCPK:IMUN, OTCPK:CRYO, OTCPK:PVOTF, OTCPK:AYTU, OTCPK:RVVTF, OTCPK:VDQSF, OTCPK:BITRF, NAS:CLSN, AMEX:IMUC, OTCPK:PTIX, OTCPK:MNTM, OTCPK:STLT, AMEX:APHB, NAS:CERC » details
Traded in other countries:44R1.Germany,
RXi Pharmaceuticals Corp is a biotechnology company focused on discovering and developing therapies addressing high unmet medical needs, in the areas of dermatology and ophthalmology.

RXi Pharmaceuticals Corp was incorporated in Delaware on September 8, 2011. It is a biotechnology company focused on discovering and developing therapies addressing high unmet medical needs, in the areas of dermatology and ophthalmology. Its development programs are based on siRNA technology and immunotherapy agents. The clinical development programs include, but are not limited to, its proprietary, self-delivering RNAi (sd-rxRNA) compounds for the treatment of dermal and retinal scarring and an immunodulating agent, Samcyprone, for the treatment of such disorders as alopecia areata, warts and cutaneous metastases of melanoma. In addition to these clinical programs, the Company has a pipeline of discovery and preclinical product candidates in its core therapeutic areas, as well as in other areas of interest. The Company's pipeline, coupled with its extensive patent portfolio, provides for the advancement to further discover and develops therapies either on its own or in collaboration with strategic partners. The Company's first clinical product candidate is RXI-109, a self-delivering RNAi compound being developed for the reduction of dermal scar formation. RXI-109 is designed to reduce the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin. RXI-109 is being developed to prevent or reduce dermal scarring following surgery or trauma, as well as for the management of hypertrophic scars and keloids. The Company competes with Alnylam Pharmaceuticals, Inc., Benitec Limited, Silence Therapeutics plc, Quark Pharmaceuticals, Inc., Tekmira Pharmaceuticals Corporation, Arrowhead Research Corporation, Dicerna Pharmaceuticals, Inc., Sylentis, S.A. and Roche Innovation Center Copenhagen A/S. The Company is subject to federal, state and local regulations relating to the use, handling, storage and disposal of hazardous materials, including chemicals and radioactive and biological materials.

Ratios

vs
industry
vs
history
PB Ratio 1.67
RXII's PB Ratio is ranked higher than
80% of the 975 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. RXII: 1.67 )
Ranked among companies with meaningful PB Ratio only.
RXII' s PB Ratio Range Over the Past 10 Years
Min: 1.41  Med: 6.77 Max: 50.29
Current: 1.67
1.41
50.29
PS Ratio 249.87
RXII's PS Ratio is ranked lower than
90% of the 774 Companies
in the Global Biotechnology industry.

( Industry Median: 13.23 vs. RXII: 249.87 )
Ranked among companies with meaningful PS Ratio only.
RXII' s PS Ratio Range Over the Past 10 Years
Min: 64.67  Med: 215.05 Max: 1450
Current: 249.87
64.67
1450
Current Ratio 2.55
RXII's Current Ratio is ranked lower than
67% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. RXII: 2.55 )
Ranked among companies with meaningful Current Ratio only.
RXII' s Current Ratio Range Over the Past 10 Years
Min: 0.48  Med: 6.65 Max: 11.98
Current: 2.55
0.48
11.98
Quick Ratio 2.55
RXII's Quick Ratio is ranked lower than
63% of the 820 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. RXII: 2.55 )
Ranked among companies with meaningful Quick Ratio only.
RXII' s Quick Ratio Range Over the Past 10 Years
Min: 0.48  Med: 6.65 Max: 11.98
Current: 2.55
0.48
11.98

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1.95
RXII's Price-to-Net-Cash is ranked higher than
85% of the 652 Companies
in the Global Biotechnology industry.

( Industry Median: 6.34 vs. RXII: 1.95 )
Ranked among companies with meaningful Price-to-Net-Cash only.
RXII' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.84  Med: 7.59 Max: 17.2
Current: 1.95
1.84
17.2
Price-to-Net-Current-Asset-Value 1.68
RXII's Price-to-Net-Current-Asset-Value is ranked higher than
87% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. RXII: 1.68 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
RXII' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.59  Med: 9.04 Max: 40.28
Current: 1.68
1.59
40.28
Price-to-Tangible-Book 1.61
RXII's Price-to-Tangible-Book is ranked higher than
84% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. RXII: 1.61 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
RXII' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.52  Med: 8.55 Max: 35.79
Current: 1.61
1.52
35.79
Price-to-Median-PS-Value 1.14
RXII's Price-to-Median-PS-Value is ranked lower than
61% of the 673 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. RXII: 1.14 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
RXII' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.35  Med: 1.01 Max: 6.28
Current: 1.14
0.35
6.28
Earnings Yield (Greenblatt) % -172.85
RXII's Earnings Yield (Greenblatt) % is ranked lower than
95% of the 1109 Companies
in the Global Biotechnology industry.

( Industry Median: -10.11 vs. RXII: -172.85 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
RXII' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -191.5  Med: 0 Max: 2672.41
Current: -172.85
-191.5
2672.41

More Statistics

Revenue (TTM) (Mil) $0.02
EPS (TTM) $ -1.36
Beta2.54
Short Percentage of Float20.91%
52-Week Range $0.60 - 3.27
Shares Outstanding (Mil)13.15

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $)
EPS ($) -1.17 -1.62 -0.75 -0.85
EPS without NRI ($) -1.17 -1.62 -0.75 -0.85
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:RXII

Headlines

Articles On GuruFocus.com
Looking Ahead of Wall Street: RXI Pharmaceuticals, Titan Pharmaceuticals, Micron Technologies Mar 30 2015 
RXi Pharmaceuticals Corp. (RXII) CEO Noah D Beerman buys 10,000 Shares Jul 12 2010 

More From Other Websites
RXi Pharmaceuticals to Present at the 5th Annual Cancer BioPartnering & Investment Forum Mar 22 2017
RXi Pharmaceuticals to Present at the 2nd Annual Oligonucleotide and Peptide Therapeutics Conference Mar 21 2017
RXi Pharmaceuticals to Webcast Fourth Quarter and Year End 2016 Financial Results on Thursday, March... Mar 16 2017
The Life Sciences Report Examines How the RXi-MirImmune Merger Is Aiming to Unlock Value Through... Feb 23 2017
Executives at Crane Manufacturer Buy Shares Amid Optimism about Infrastructure Spending Boost, Plus... Feb 22 2017
RXi Pharmaceuticals Appoints Medical Oncology Expert, Dr. James Griffin, to Scientific Advisory... Feb 14 2017
RXi Pharmaceuticals to Present at Leading Investor and Healthcare Conferences Feb 08 2017
RXi Pharmaceuticals Appoints Leading Oncology Expert, Dr. Rolf Kiessling, to Scientific Advisory... Feb 07 2017
RXI PHARMACEUTICALS CORP Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued... Feb 03 2017
Retired CEO of NBT Bancorp Inc. (NBTB) Offloads Shares, Plus Other Exciting Insider Trading Jan 27 2017
Mild Insider Selling at PriceSmart Inc. (PSMT) and ANSYS Inc. (ANSS); Insider Buying at Three Other... Jan 20 2017
RXI PHARMACEUTICALS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in... Jan 10 2017
RXi Pharmaceuticals Completes Acquisition of MirImmune Inc. and Appoints New Chief Business Officer Jan 09 2017
RXi Pharmaceuticals to Present at the 9th Annual Biotech Showcase™ Dec 26 2016
RXI PHARMACEUTICALS CORP Financials Dec 22 2016
RXI PHARMACEUTICALS CORP Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in... Dec 21 2016
RXi Pharmaceuticals Announces Closing of $11.5 Million Underwritten Public Offering and Full... Dec 21 2016
RXI PHARMACEUTICALS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Dec 19 2016
Abercrombie & Fitch, Hanesbrands Dip into Friday’s 52-Week Low Club Dec 16 2016
RXi Pharmaceuticals Announces Pricing of $10 Million Underwritten Public Offering Dec 16 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)